Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Haleon plc announced the redemption of its total outstanding $300 million Callable Floating Rate Senior Notes due 2024 by its subsidiary, GSK Consumer Healthcare Capital US LLC. The redemption is set for March 24, 2023, at a price equal to 100% of the principal amount plus any accrued interest. All noteholders will receive a notice of redemption from the trustee, Deutsche Bank Trust Company Americas, and the notes must be surrendered to collect the redemption price. This move underlines Haleon's financial strategy as it manages its debt obligations.
Haleon plc (LSE: HLN, NYSE: HLN) announced the expiration and final results of its exchange offers for seven series of unregistered notes issued by GSK Consumer Healthcare Capital. The offers, launched on September 29, 2022, expired on October 28, 2022. The Exchange Notes, which have been registered under the Securities Act, will replace the Original Notes. Settlement is expected on November 2, 2022. The primary aim was to provide holders of Original Notes with registered securities, eliminating prior transfer restrictions.
Haleon and Microsoft have partnered to enhance health product accessibility for individuals who are blind or have low vision. Launched on World Sight Day, the collaboration improves the Microsoft Seeing AI app, enabling detailed audio narrations for over 1,500 Haleon products across the U.S. and U.K. Users can scan barcodes to receive crucial information about product name, ingredients, and usage. This initiative aims to empower users in managing their health independently. Haleon also introduced its Health Inclusivity Index, aiming to enhance global health inclusivity.
Haleon plc (LSE: HLN, NYSE: HLN) announced the start of exchange offers for seven series of outstanding unregistered notes from GSK Consumer Healthcare Capital. The offers aim to exchange these unregistered notes for registered notes under the Securities Act, expected to be listed on the NYSE. The exchange period ends at 5:00 p.m. (Eastern time) on October 28, 2022, with settlement anticipated on November 2, 2022. A registration statement related to the exchange notes was filed with the SEC on the same date.
New results from the COSMOS-Mind study indicate that participants taking Centrum Silver exhibited significant improvements in cognitive function compared to those on placebo. This study, involving over 2,000 older adults, highlights the potential benefits of multivitamin supplementation in addressing cognitive decline, a major concern as aging populations grow. The findings suggest that Centrum Silver could enhance memory and executive function, stressing its importance for healthy aging. The detailed report is available in the Alzheimer & Dementia Journal.
Nicorette has launched SmokeLess Break Beats, a unique music therapy initiative aimed at supporting smokers in their cessation journey. Developed with Berklee Music and Health Institute, the program features eight original tracks designed to promote relaxation, focus, and confidence. Available for free on Spotify, these playlists serve as behavioral tools during typical smoke breaks. The initiative underscores the science behind music's ability to reduce cravings and enhance psychological well-being, increasing the effectiveness of Nicotine Replacement Therapy by up to 70%.
Haleon, a leading independent consumer health company, has officially launched following its demerger from GSK plc. Trading on the London Stock Exchange began on July 18, 2022, with NYSE trading set to follow on July 20, 2022. Haleon boasts a robust brand portfolio, including Advil, Sensodyne, and TUMS, targeting an annual organic revenue growth of 4-6%. The company aims to address everyday health challenges and empower 50 million people by 2025. Haleon emphasizes its commitment to scientific innovation and consumer-centric solutions, focusing on the growing self-care market.